Global pharmaceutical major Lupin Limited has been featured for the first time in the Dow Jones Best-in-Class (DJBIC) Indices for 2026. This milestone recognizes the company’s strong commitment to sustainable and ethical business practices. Lupin has been listed in both the DJBIC World Index and the DJBIC Emerging Markets Index, marking a significant achievement in its ongoing sustainability journey following an industry-leading score of 91/100 in the S&P Global Corporate Sustainability Assessment.
Recognized for Sustainability Leadership
Lupin’s inclusion in the Dow Jones Best-in-Class Indices highlights its exceptional performance across Environmental, Social, and Governance (ESG) parameters. This recognition by a global benchmark underscores the company’s long-term value creation agenda and its dedication to responsible growth and financial discipline. The indices measure the performance of companies selected from an underlying universe based on specific, rigorous sustainability criteria.
Strategic Significance
According to Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU at Lupin, this inclusion serves as a testament to the strength of the company’s governance framework. By achieving a score of 91/100 in the S&P Global CSA 2025, Lupin previously solidified its status among the top 1% of companies globally. This new milestone further strengthens the organization’s credibility with global investors and enhances its competitive positioning in the pharmaceutical sector.
Commitment to Future Excellence
Looking ahead, the company continues to integrate science-based targets into its operations. Key focus areas include environmental stewardship, the maintenance of high quality and safety standards, and responsible supply chain management. These initiatives are designed to improve patient health outcomes globally while ensuring the company maintains its standing as a leader in sustainable business practices.
Source: BSE
